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Introduction: Localized amyloidosis in the head and neck is a rare and generally benign condition. In the oral
cavity, amyloidosis usually involves the tongue or buccal mucosa. We present the second case of oral amyloidosis
arising in the gingiva ever reported, to the best of our knowledge.
Case presentation: A 73-year-old White Spanish man presented a persistent nodular mass involving his upper
gingiva. The lesion was surgically resected and the histological examination revealed a subepithelial, multinodular
amorphous and fibrillar accumulation. Staining of the specimen for Congo red proved positive, exhibiting a reddish
colour under light microscopy and apple-green birefringence under polarized light. With immunohistochemical
tests, pentagonal amyloid component was demonstrated. An extensive study excluded any systemic involvement; a
diagnosis of localized primary amyloidosis was made. After 2 years of follow-up, no clinical progression to systemic
amyloidosis or local recurrence was observed.
Conclusions: Localized amyloidosis of the gingiva is an extremely rare condition that seems to show no clinically
distinct feature. Histologic examination is the first step towards diagnosis, followed by immunohistochemical tests.
The diagnosis of localized amyloidosis should always be integrated with blood tests, a bone marrow biopsy,
echocardiography and digestive endoscopy to intercept systemic involvement.
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Amyloidosis is a progressive metabolic disease character-
ized by abnormal deposits of the protein amyloid in one
or more organs. The term was coined by Virchow in
1854 in order to describe abnormal extracellular mater-
ial seen in the liver during an autopsy [1]. The amyloido-
genic protein is the basic component of about 25
different protein structures that can misfold and aggre-
gate in insoluble beta-pleated-sheet structures, which are
deposited in the extracellular space of different tissues
and finally cause functional impairment [2].
This disease may be acquired or hereditary. Also, it
can be restricted to a single organ, where the amyloid is
both produced and deposited, such as the lungs, the
brain, or the skin (localized form) with an excellent
prognosis, or may affect many organs of the body, leading
to significant morbidity and mortality (systemic form).
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unless otherwise stated.is between 5 and 15 months, depending on which parts of
the body are affected. Death is commonly caused by kid-
ney failure or arrhythmic episodes. Localized forms have
instead an excellent prognosis, in particular when the head
and neck district is affected [3].
Amyloidosis can be classified according to its cause:
primary, secondary and familial (common in some areas,
as Portugal, Japan and Israel). The subtypes of amyloid-
osis are currently classified on the basis of the specific
protein that is deposited, using the prefix A for amyloid,
followed by one or more letters that indicate the name
of the protein [2]. AL and AA amyloidosis are the most
common and known subtypes.
Primary systemic amyloidosis, also known as amyloid
light-chain (AL) amyloidosis, is thought to be related
with monoclonal gammopathies, in which amyloid-
forming immunoglobulin light chains are produced. AL
amyloidosis is associated with plasma cell dyscrasia and
multiple myeloma; the most commonly affected organs
are the kidneys, the liver, the heart and the nerves [2].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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osis (AA form) usually have other chronic infectious or
inflammatory diseases, such as osteomyelitis, tubercu-
losis, rheumatoid arthritis, or Crohn's disease. Almost all
organs can be affected, most often the kidneys, the liver,
and the spleen.
Localized amyloidosis in the head and neck is a rare
and generally benign condition. The most common sites
of involvement are the thyroid, the larynx and subglottis,
whereas in the oral cavity, amyloidosis usually tends to
involve the tongue or buccal mucosa [4,5]. We present
the second case of oral amyloidosis arising in the gingiva
ever reported, to the best of our knowledge [6].Case presentation
A 73-year-old White Spanish man was referred to our
Department with a 12-month history of difficulty wear-
ing his full upper denture. Clinical examination revealed
a nodular mass involving the upper gingiva that was pos-
sibly due to his nonretentive and ill-fitting upper denture
(Figure 1).
The patient was surgically treated with resection of the
whole lesion and primary closure of the surgical wound.
Macroscopically, the surgical specimen measured 6cm ×
1.4cm × 1.5cm and was a nodular mass covered by normal
mucosa. Histological examination showed a subepithelial,
multinodular amorphous and fibrillar accumulation
(Figures 2A and 2B). The amorphous material had positive
staining for Congo red, exhibiting a reddish colour under
light microscopy (Figures 2C and 3) and apple-green bi-
refringence under polarized light (Figures 2D and 4). With
immunohistochemical tests, pentagonal amyloid compo-
nent (AP) was demonstrated, whereas the result of the test
for AA amyloidosis, with the use of specific monoclonal
antibodies, was negative. The patient was submitted to
extensive study in order to discover associated systemic
diseases or other possible sites of amyloid deposition.
Laboratory test results, a bone marrow biopsy, echocar-
diography and digestive endoscopy excluded any otherFigure 1 Clinical view of the upper gingiva before surgery.haematological/immunological disorder or organ dys-
function. From the integration of clinical, laboratory and
histological findings, a diagnosis of localized primary
amyloidosis was made. After 2 years of follow-up, no
clinical progression to systemic amyloidosis or local re-
currence was observed.
Discussion
Amyloidosis is a relatively rare disease, in which local-
ized and systemic forms have differing prognoses, thus
requiring different management regimes.
Stem cell transplantation is the gold standard for treat-
ment of primary systemic amyloidosis, but it is not al-
ways suitable, depending on the age of the patient,
progression of the disease and haematological markers.
Combinations of chemotherapy and immunomodulatory
agents are an alternative [7,8].
The treatment of localized amyloidosis depends on the
organ involved and the grade of functional impairment,
being symptomatic most of the time. Follow-up is always
required to detect systemic progression [9-13].
Oral localized amyloidosis is not generally associated
with systemic amyloidosis and does not usually progress
to systemic forms [14].
The AP form of amyloid found in this case has a non-
fibrillar structure and represents approximately 10% of
the amyloid deposits. It has been demonstrated that AP
is an alpha-1 globulin, a normal component of the
serum, normally found in vascular basal membranes. It
drastically increases in some pathologic conditions as
vasculitis, arteriosclerosis, and glomerular nephropa-
thies. None of these conditions has been found in the
present case.
Gingival biopsy, in cases in which amyloidosis is sus-
pected, should avoid areas affected by gingivitis and
should extend beyond the mucogingival junction, where
many fibrous structures are present and where amyloid is
more likely to be deposited [4]. Occasionally, gingival bi-
opsy is also preferred, in absence of any gingival lesion, in
some cases of suspected systemic amyloidosis where the
biopsy of the organs involved is at high risk of morbidity.
After a diagnosis of oral amyloidosis, it is crucial to ex-
clude a systemic involvement. In fact, 25% of the pa-
tients with systemic amyloidosis show macroglossia. In
this condition, the tongue loses mobility and the patient
can lose the ability of retracting it behind the lips. Differ-
ential diagnosis with malignant neoplasia must be made
considering the absence of ulcerations, pain, bleeding,
and adenopathy. In addition, in cases of a carcinoma,
the consistency of the tongue is harder [15].
Petechiae, papulae and ulcers can also appear on the
oral mucosa, and the involvement of the salivary glands
can produce xerostomia [3]. Vascular involvement can
produce angiopathy and bleeding [16].
Figure 2 Histological and immunohistochemical tests. (A) Panoramic section (haematoxylin and eosin: ×0.6). (B) Irregular acanthosis,
lymphocytic infiltration and amyloid deposits (haematoxylin and eosin: ×4). (C) Congo red stain of amyloid (×10). (D) Congo red stain showing
characteristic apple-green birefringence (arrows) under polarized light (×60).
Figure 3 Congo red staining (×10). Amyloid material under the
mucosal epithelium –detail.
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struction and the lesions can be exacerbated by the in-
flammation of the periodontium [17].
Association between amyloidosis and calcifying odon-
togenic tumour has also been described [18].
Conclusions
Local amyloidosis of the gingiva is an extremely rare
condition that can present as an unspecific nodularFigure 4 Congo red staining under polarized light (×60) – detail.
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thologists as well as general practitioners should be able
to cooperate for the diagnosis, treatment and follow-up.
Histologic examination is the first step towards diagno-
sis, followed by immunohistochemical tests. The diagno-
sis of localized amyloidosis should always be followed by
blood tests, a bone marrow biopsy, echocardiography
and digestive endoscopy to intercept systemic amyloid-
osis or any other haematological/immunological disorder
or organ dysfunction.
There is no consensus on the management of local
amyloidosis. Surgical treatment of localized forms is in-
dicated to reduce the functional impairment produced
by a voluminous mass (for example, a progressive en-
largement of the tongue can produce an oropharyngeal
blockage, with obstruction of the upper airways). In the
present case, we performed surgical excision of the le-
sion in order to obtain satisfactory retention of the pa-
tient’s full upper denture. In any case, follow-up is
mandatory, both to manage recurrences of the lesions
and, mostly, to monitor the possible evolution of the dis-
ease to the systemic form.
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